ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
LeadLI
LB Investment
Activity from announced rounds
Activity in this selectionnrw-venture-f5757e51
- Rounds participated in
- 4
- Confirmed lead rounds
- 1 3 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $321M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionPoint2 Technology
Develops RF-based interconnect technology for AI data-center and automotive networking
$136MSeries B
Role not disclosedCarbonSix
Develops deployment-ready robotic intelligence and automation solutions for manufacturing
$40MSeries A
Role not disclosedXCENA
Builds CXL computational memory chips and SDK for AI infrastructure in hyperscalers, telcos, and research
$135MSeries B
Role not disclosed